Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Research Article Volume 5 Issue 8

Preoperative Transarterial Chemoinfusion in the Treatment of Patients with Gastric Cancer

Arybzhanov DT1,3*, Gantsev ShKh2 and Sburov AR1,2

1The Head of the Department of Chemotherapy and Endovascular Oncology of Shymkent City Cancer Center, Candidate of Medical Science, Professor of the Department of Surgical Disciplines No. 2 of South-Kazakhstan Medical Academy, Kazakhstan
2Professor, the Head of the Department of Oncology with the courses of Institute of Postgraduate Education in Oncology and Pathological Anatomy of Bashkir State Medical University, Ufa, Russia
3Oncologist, Postgraduate Student of the Department of Oncology with the courses of Institute of Postgraduate Education in Oncology and Pathological Anatomy of Bashkir State Medical University, Ufa, Russia

*Corresponding Author: Arybzhanov DT, The Head of the Department of Chemotherapy and Endovascular Oncology of Shymkent City Cancer Center, Candidate of Medical Science, Professor of the Department of Surgical Disciplines No. 2 of South-Kazakhstan Medical Academy, Kazakhstan.

Received: July 21, 2022; Published: July 29, 2022

Abstract

Nowadays, the technique of intra-arterial chemotherapy in primary patients with gastric cancer can be considered as an effective, low-toxic method of treatment. Preoperative intra-arterial chemotherapy may be the method of choice for improving the survival and quality of life of patients with gastric cancer.

Nowadays, results of the diagnosis and treatment of gastric cancer (GC) are still unsatisfactory. With the development of modern catheters and angiographic devices, regional chemotherapy in patients with gastric cancer has become more often used in clinical practice.

Goal of the research: Improving the response to treatment of patients with gastric cancer using regional intra-arterial chemotherapy (RIAC).

Materials and methods: There were analyzed short and long-term results of combination therapy of 110 patients with gastric cancer for the period of 2005-2020. The average age of patients was 59.2 ± 4.3 years old. The incidence of neoplastic process according to the TNM classification was as follows: T3N0M0 - 37 (33.63%) patients, T3N1M0 - 41 (37.27%) patients and T3N2M0 - 32 (29.1%) patients. Histologically, various forms of adenocarcinoma were diagnosed in all patients

All patients underwent the first stage of neoadjuvant intra-arterial chemotherapy (RIAC) according to the DPF scheme (Docetaxel 75mg/m2 + Cisplatin 75mg/m2 + Fluorouracil 1000mg/m2 on the 1st day), it comprised 2 cycles with an interval of 28 days, and then, there was performed surgery.

Results and their discussion: Short-term results of RIAC showed the effectiveness of treatment after 2 cycles of neoadjuvant intra-arterial regional chemotherapy; 93 (84.5%) patients showed partial regression, 17 (15.5%) patients showed stabilization of the process. These patients underwent radical surgery with the second stage of combination therapy - extended gastrectomy with D2 lymphodissection.

The medicinal pathomorphosis of 1-2 grade was represented in 34 (30.9%) patients, pathomorphosis of the 3rd grade was represented in 38 (34.5%) patients, pathomorphosis of the 4th grade - 9 (8.1%) patients. The case follow-up showed the following results: 9 (8.1%) patients lived for 6 months, 63 (57.2%) patients lived for 12 months, 59 (53.3%) patients lived for 18 months, 57 (51.8%) patients lived for 24 months, 47 (42.7%) patients lived for 36 months, 41 (37.2%) patients lived for 48 months and 35 (31.8%) patients continue to live for 60 months or more. Median survival was 51.8 +1.5 months.

Conclusion: Neoadjuvant RIAC in the treatment of patients with gastric cancer was effective in 84.5% of patients. In 42.6% of patients, there was represented therapeutic pathomorphosis of 3-4 grade. The 3 and 5-year survival rates were 42.7% and 31.8%, respectively. Median survival was 51.8 +1.5 months

Keywords: Gastric Cancer; Intra-Arterial Chemotherapy; Surgical Treatment; Survival

References

  1. Kaprin AD. “Malignant neoplasms in Russia in 2016 (morbidity and mortality). Federal Government Budgetary Institution “National Medical Research Center named after P.A.Herzen of the Ministry of Health of Russia 250 (2018).
  2. Kaidarova DR. “Indicators of oncological service of the Republic of Kazakhstan for 2019 (statistical and analytical materials)”. Almaty 137 (2020).
  3. https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
  4. Abdollah MH., et al. “Lack of Any Relationship of Stomach Cancer Incidence and Mortality with Development in Asia”. Asian Pacific Journal of Cancer Prevention 17.8 (2016): 3775-3781.
  5. Smyth EC., et al. “Gastric cancer”. Lancet 396.10251 (2020): 635-648.
  6. Zyryanov BN., et al. “Combined treatment with intra-arterial regional chemotherapy for locally advanced stomach cancer”. Russian Oncological Journal 1 (1997): 17-20.
  7. Barone C., et al. “Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer”. Oncology 67.1 (2004): 48-53.
  8. Wang J., et al. “Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only”. Oncology Letters 15.4 (2018).
  9. Song Z., et al. “Progress in the treatment of advanced gastric cancer”. Tumor Biology 39.7 (2017): 1010428317714626.
  10. Choi AH., et al. “Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond”. World Journal of Gastroenterology 21.24 (2015): 7343-734
  11. Johnston FM and Beckman M. “Updates on Management of Gastric Cancer”. Current Oncology Reports 21.8 (2019): 67.
  12. Ikegame K and Terashima M. “Perioperative Chemotherapy for Gastric Cancer”. Gan To Kagaku Ryoho4 (2020): 569-573.
  13.  

Citation

Citation: Arybzhanov DT., et al. “Preoperative Transarterial Chemoinfusion in the Treatment of Patients with Gastric Cancer". Acta Acta Scientific Gastrointestinal Disorders 5.8 (2022): 58-61.

Copyright

Copyright: © 2022 Arybzhanov DT., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US